A meta-analysis pooling six randomized clinical trials assessing anti-tau protein monoclonal antibodies for AD concluded that semorinemab and tilavonemab demonstrated relatively good efficacy based on MMSE and ADAS-Cog, as well as the safety profile. This evidence concerns the gene MAPT and Alzheimer disease.